Cerebras Systems completed its initial public offering at a $240 million raise this week, while Eikon Therapeutics separately lifted $381 million in its own float, marking a rare dual-sector convergence in venture-backed IPO activity. Both companies entered public markets within seventy-two hours of each other, the first sustained venture-exit window since Q2 2021.

Cerebras, the Sunnyvale wafer-scale compute builder, priced at the midpoint of its revised range and traded up 11% on first-day volume. The company ships single-chip systems that rival NVIDIA's clustered GPU arrays for transformer training, with disclosed customers including Pfizer and GlaxoSmithKline research arms. Eikon, a Hayward-based biotech using high-speed microscopy for small-molecule discovery, priced at the top of its $16-$18 range and closed flat. Both offerings arrived under the same underwriting syndicate: Morgan Stanley, Goldman Sachs, and Jefferies.

The dual pricing matters because it reopens the venture liquidity pathway that has been sealed since regional bank collapses last March throttled IPO appetite. Cerebras had filed for public listing in April 2023 but withdrew after market reception turned negative. Eikon filed in July 2024 and waited five months to price. The window's reopening is narrow—both companies carry institutional weightings above 78%, meaning retail allocation was minimal and the float remains controlled. That structure allows for a disciplined secondary market, but it also signals limited distribution appetite outside existing LP bases.

What connects these offerings is their shared dependence on compute-heavy infrastructure. Cerebras sells the hardware; Eikon consumes it. The company's platform processes 1.6 million images per experimental run, requiring on-premises clusters that historically burned $4-$7 million annually in depreciation alone. Eikon's S-1 filing disclosed partnerships with Recursion Pharmaceuticals and Insitro, both of which are themselves compute-intensive biotech plays backed by Nvidia Ventures and SoftBank respectively. The compute thesis now spans both sides of the capital stack: the builders and the burners.

Operators should watch for the 90-day lockup expirations on both stocks, expected mid-June 2025, which will test whether institutional holders view these as long-duration platform plays or tactical liquidity events. Cerebras faces additional scrutiny from export controls; its wafer-scale chips exceed dimensional thresholds under current BIS guidelines, which could limit access to Gulf and Asian research buyers. Eikon's path depends on whether its first disclosed partnership revenue—expected in Q3 2025 filings—validates the microscopy platform as a monetizable service layer or remains a cost center.

Neither company is profitable. Cerebras reported a $127 million net loss on $278 million revenue in its last twelve months. Eikon disclosed a $91 million loss on $0 revenue, as its platform remains pre-commercial. Both companies are now obligated to report quarterly, which will surface burn rates and customer concentration risk that private filings obscured. The market is pricing both at 4.2x forward revenue estimates, assuming Cerebras hits $580 million in 2025 sales and Eikon achieves $90 million in partnership fees by 2026. Those multiples reflect caution, not enthusiasm, and leave little room for execution variance.